| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01075204 | Respiratory Tract Infection | Drug: clarithromycin modified release 500 mg | Abbott|Eilaf CRO | | 2011-01-01 | 2013-02-06 |
| NCT02052336 | Healthy | Drug: CJ-12420 200mg + Clarithromycin 500mg|Drug: CJ-12420 200mg|Drug: Clarithromycin 500mg | CJ HealthCare Corporation | Phase 1 | 2013-10-01 | 2016-12-13 |
| NCT01223690 | Sepsis|Severe Sepsis|Septic Shock | Drug: Clarithromycin|Drug: Dextrose 5% | University of Athens | Phase 3 | 2007-07-01 | 2011-08-03 |
| NCT00269386 | Crohn's Disease | Drug: Clarithromycin|Drug: Placebo | Royal Liverpool University Hospital|Abbott | Phase 3 | 2000-04-01 | 2009-01-06 |
| NCT01521364 | Multidrug-resistant Tuberculosis|Extensively Drug-resistant Tuberculosis | Drug: Addition of different doses of clarithromycin. | University Medical Center Groningen | Phase 4 | 2011-12-01 | 2013-05-27 |
| NCT01146600 | Hypersomnia|Idiopathic Hypersomnia|Narcolepsy | Drug: Clarithromycin followed by placebo|Drug: Placebo then Clarithromycin | Lynn Marie Trotti|Emory University | Phase 2 | 2010-07-01 | 2014-08-25 |
| NCT01421706 | Healthy | Drug: Sibutramine-clopidogrel|Drug: sibutramine-Clarithromycin | Inje University | Phase 1 | 2008-07-01 | 2012-09-16 |
| NCT02080780 | CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction] | Drug: Clarithromycin XL|Drug: 2% Diltiazem | Ventrus Biosciences, Inc|TKL Research, Inc. | Phase 1 | 2013-09-01 | 2014-03-07 |
| NCT02416570 | Cachexia|Lung Cancer | Drug: Clarithromycin|Drug: Placebo | University of Nottingham|Roy Castle Lung Cancer Foundation | Phase 2 | 2015-04-01 | 2016-09-15 |
| NCT02573935 | Multiple Myeloma | Drug: Clarithromycin|Drug: Placebo|Drug: VCD induction therapy | Henrik Gregersen|Danish Myeloma Study Group|Aalborg Universitetshospital | Phase 2 | 2015-01-01 | 2016-09-19 |
| NCT01851954 | Very Low Birth Weight Infant|Ureaplasma/Mycoplasma Positive | Drug: Clarithromycin | Seoul National University Hospital | Phase 2 | 2013-02-01 | 2014-11-17 |
| NCT03043989 | Prostate Cancer | Drug: Docetaxel|Drug: Cabazitaxel|Drug: Clarithromycin | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2017-02-15 | 2017-02-13 |
| NCT00648830 | Healthy | Procedure: Clarithromycin|Drug: Clarithromycin | Mylan Pharmaceuticals|Genpharm ULC | Phase 1 | 2004-05-01 | 2008-03-31 |
| NCT02807051 | Drug Interaction Study | Drug: Pacritinib|Drug: Clarithromycin|Drug: Pacritinib and Clarithromycin | CTI BioPharma|Covance | Phase 1 | 2014-09-01 | 2016-06-20 |
| NCT00719420 | Helicobacter Pylori Infection | Drug: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Drug: Clarithromycin, Amoxicillin, Omeprazole | University of North Texas Health Science Center|Universidad del Valle, Colombia|Vanderbilt University | Phase 3 | 2006-04-01 | 2008-07-18 |
| NCT01516606 | Lymphoma | Drug: clarithromycin, oral, high dose | Andres J. M. Ferreri|IRCCS San Raffaele | Phase 2 | 2012-01-01 | 2012-01-19 |
| NCT01385683 | Healthy | Drug: Dabigatran then dabigatran and clarithromycin|Drug: Clarithromycin and dabigatran then dabigatran | Centre Hospitalier Universitaire de Saint Etienne|Groupe de Recherche sur la Thrombose | Phase 1 | 2011-06-01 | 2012-03-21 |
| NCT02998437 | Drug Interaction Potentiation | Drug: Ilaprazole 10mg|Drug: Clarithromycin 500mg|Drug: Amoxicillin 500 Mg | Il-Yang Pharm. Co., Ltd.|Severance Hospital | Phase 1 | 2016-12-01 | 2017-01-24 |
| NCT02774902 | Healthy Volunteers | Drug: TAK-438|Drug: Clarithromycin | Takeda | Phase 1 | 2010-08-01 | 2016-05-13 |
| NCT02829983 | Aggressive Periodontitis | Drug: Clarithromycin|Drug: Placebo|Other: One-stage full-mouth ultrasonic debridement (FMUD) | Universidade Estadual Paulista Jlio de Mesquita Filho|Coordenao de Aperfeioamento de Pessoal de Nvel Superior. | | 2014-03-01 | 2016-07-12 |
| NCT00297674 | Sepsis|Ventilator Associated Pneumonia | Drug: Intravenous Clarithromycin | University of Athens | Phase 4 | 2004-06-01 | 2006-02-27 |
| NCT00461084 | Lymphoma | Drug: BIAXIN (CLARITHROMYCIN)|Drug: Biaxin (clarithromycin) | Memorial Sloan Kettering Cancer Center | Phase 2 | 2007-04-01 | 2014-09-17 |
| NCT02286635 | Healthy Volunteers | Drug: Deflazacort and rifampin|Drug: Deflazacort and Clarithromycin | Marathon Pharmaceuticals, LLC | Phase 1 | 2014-11-01 | 2016-01-06 |
| NCT00121550 | Heart Disease|Cardiovascular Disease | Drug: clarithromycin | Copenhagen Trial Unit, Center for Clinical Intervention Research|Danish Heart Foundation|Copenhagen Hospital Corporation|The Danish Medical Research Council|The 1991 Pharmacy Foundation|Abbott | Phase 3 | 1999-10-01 | 2016-08-10 |
